Meperidine

Meperidine

SCHEMBL194412

CCOC(=O)C1(c2ccccc2)CCN(C)CC1.CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1

The experimentally established mechanism targets of Meperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 11/20 1.00
OPRD1 P41143 5/20 0.97
OPRK1 P41145 5/20 0.97
SLC22A1 O15245 1/20 0.97
SLC6A4 P31645 1/20 0.97
ADRA1A P35348 1/20 0.97
KCNH2 Q12809 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meperidine SCHEMBL1083668 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL2860723 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL41046 1.00 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL25431 0.99 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL28905219 0.97 OPRM1 (0.97) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL27945061 0.97 OPRM1 (0.97) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL28695347 0.96 OPRM1 (0.94) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL3054250 0.96 OPRM1 (0.94) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Ethoheptazine SCHEMBL24581 0.93 OPRM1 (0.90) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL12574647 0.89 OPRM1 (0.82) OPRM1OPRD1OPRK1SLC22A1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9427435-B2 Narcotic emulsion formulations for treatment of cancer pain TEIKOKU PHARMA USA, INC. (US) 2016-08-30 US disclosed
US-20150141461-A1 Narcotic Emulsion Formulations for Treatment of Cancer Pain TEIKOKU PHARMA USA, INC. 2015-05-21 US disclosed
US-8871791-B2 Narcotic emulsion formulations for treatment of cancer pain TEIKOKU PHARMA USA, INC. (US) 2014-10-28 US disclosed
EP-2400838-A1 NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN Teikoku Pharma USA, Inc. (US) 2012-01-04 EP disclosed
WO-2010098897-A1 NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN TEIKOKU PHARMA USA, INC. (US) 2010-09-02 WO disclosed
US-20100216842-A1 Narcotic Emulsion Formulations for Treatment of Cancer Pain TEIKOKU PHARMA USA INC. 2010-08-26 US disclosed
US-7674482-B2 for producing acetylcholine and serotonin; improved cognitive function, induced and maintained sleep, reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, appetite, and treating depression TARGETED MEDICAL PHARMA INC. (US) 2010-03-09 US disclosed
EP-1996213-A2 METHOD AND COMPOSITIONS FOR POTENTIATING PHARMACEUTICALS WITH AMINO ACID BASED MEDICAL FOODS Shell, William E. (US) 2008-12-03 EP disclosed
WO-2007111958-A2 METHOD AND COMPOSITIONS FOR POTENTIATING PHARMACEUTICALS WITH AMINO ACID BASED MEDICAL FOODS SHELL WILLIAM E (US) 2007-10-04 WO disclosed
US-20060159726-A1 for producing acetylcholine and serotonin; improved cognitive function, induced and maintained sleep, reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, appetite, and treating depression TARGETED MEDICAL PHARMA, INC. 2006-07-20 US disclosed